<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02128321</url>
  </required_header>
  <id_info>
    <org_study_id>9766-CL-0053</org_study_id>
    <nct_id>NCT02128321</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine</brief_title>
  <official_title>A Phase 1 Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Basilea Pharmaceutica International Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of multiple doses of isavuconazole on the&#xD;
      pharmacokinetics of Repaglinide and possible metabolites after single dose administration. In&#xD;
      addition, this study will assess the effect of multiple doses of isavuconazole on the&#xD;
      pharmacokinetics of caffeine and possible metabolites after single dose administration.&#xD;
      Safety and tolerability of isavuconazole alone and in combination with Repaglinide or in&#xD;
      combination with caffeine will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma repaglinide and possible metabolite concentration: Area under the concentration-time curve from time of dosing to the last quantifiable concentration (AUClast)</measure>
    <time_frame>Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma repaglinide and possible metabolite concentration: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf)</measure>
    <time_frame>Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma repaglinide and possible metabolite concentration: Maximum concentration (Cmax)</measure>
    <time_frame>Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of caffeine and possible metabolite concentration: Area under the concentration-time curve from time of dosing to the last quantifiable concentration (AUClast)</measure>
    <time_frame>Days 3 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of caffeine and possible metabolite concentration: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf)</measure>
    <time_frame>Days 3 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of caffeine and possible metabolite concentration: Maximum concentration (Cmax)</measure>
    <time_frame>Days 3 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma isavuconazole concentration: Trough concentration (Ctrough)</measure>
    <time_frame>Days 10-18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma isavuconazole concentration: Area under the concentration-time curve during the time interval between consecutive dosing (AUCtau)</measure>
    <time_frame>Days 13, 14 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma isavuconazole concentration: Maximum concentration (Cmax)</measure>
    <time_frame>Days 13, 14 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma isavuconazole concentration: Time after dosing when Cmax occurs (tmax)</measure>
    <time_frame>Days 13, 14 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed through adverse events</measure>
    <time_frame>up to Day 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed through clinical laboratory evaluations</measure>
    <time_frame>up to Day 18</time_frame>
    <description>Laboratory assessments will include hematology, serum chemistry and urinalysis parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12-lead electrocardiograms (ECGs)</measure>
    <time_frame>up to Day 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed through vital signs</measure>
    <time_frame>up to Day 18</time_frame>
    <description>Vital signs will be measured including oral temperature, pulse, and sitting blood pressure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics of Repaglinide</condition>
  <condition>Pharmacokinetics of Caffeine</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Isavuconazole + Repaglinide + Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isavuconazole three times a day on Days 5 and 6 and once a day on Days 7 through 17, repaglinide on Days 1 and Day 14, caffeine on Days 3 and 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isavuconazole</intervention_name>
    <description>oral</description>
    <arm_group_label>Isavuconazole + Repaglinide + Caffeine</arm_group_label>
    <other_name>BAL4815</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>oral</description>
    <arm_group_label>Isavuconazole + Repaglinide + Caffeine</arm_group_label>
    <other_name>PrandinÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>oral</description>
    <arm_group_label>Isavuconazole + Repaglinide + Caffeine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has a body weight of at least 50 kg and a body mass index of 18.5 to 32&#xD;
             kg/m2, inclusive&#xD;
&#xD;
          -  The subject's 12-lead electrocardiogram (ECG) is normal&#xD;
&#xD;
          -  The subject's clinical laboratory test results are within normal limits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has any history or evidence of any clinically significant cardiovascular,&#xD;
             gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic,&#xD;
             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major&#xD;
             disease or malignancy&#xD;
&#xD;
          -  Female subject has been pregnant within 6 months before screening or breast feeding&#xD;
             within 3 months before screening&#xD;
&#xD;
          -  The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac&#xD;
             arrhythmia or torsade de pointes, structural heart disease, or family history of&#xD;
             either Short or Long QT syndrome (suggested by sudden death of a close relative at a&#xD;
             young age due to possible or probable cardiac causes). QT is the time between the&#xD;
             start of the Q wave and the end of the T wave in the heart's electrical system&#xD;
&#xD;
          -  The subject has/had febrile illness or symptomatic, viral, bacterial (including upper&#xD;
             respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to&#xD;
             clinic admission&#xD;
&#xD;
          -  The subject has received a vaccination within the last 30 days prior to study drug&#xD;
             administration&#xD;
&#xD;
          -  The subject has a positive serology test for Hepatitis B surface antigen (HBsAg),&#xD;
             Hepatitis A Immunoglobulin M antibody (anti HAV (IgM)), Hepatitis C antibody&#xD;
             (anti-HCV), or human immunodeficiency virus (anti-HIV 1+2)&#xD;
&#xD;
          -  The subject has a known or suspected allergy to any of the components of the trial&#xD;
             products or the azole class of compounds, or a history of multiple and/or severe&#xD;
             allergies to drugs or foods, or a history of severe anaphylactic reactions&#xD;
&#xD;
          -  The subject has used tobacco or nicotine containing products in the last 6 months&#xD;
&#xD;
          -  The subject has had treatment with any prescribed or non-prescribed drugs (including&#xD;
             vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior with&#xD;
             the exception of hormonal methods of contraception, hormone replacement therapy, or&#xD;
             occasional use of acetaminophen up to 2 g/day&#xD;
&#xD;
          -  The subject has participated in any interventional clinical study or has received any&#xD;
             investigational drugs within past 30 days or 5 half-lives, whichever is longer&#xD;
&#xD;
          -  The subject has had any significant blood loss, donated one unit (450 mL) of blood or&#xD;
             more, or received a transfusion of any blood or blood products within 60 days or&#xD;
             donated plasma within 7 days prior to clinic admission&#xD;
&#xD;
          -  The subject anticipates an inability to abstain from alcohol or caffeine use for 48&#xD;
             hours prior and throughout the duration of the study; or from grapefruit, grapefruit&#xD;
             juice, star fruit, or Seville oranges or any products containing these items from 72&#xD;
             hours prior and throughout the duration of the study&#xD;
&#xD;
          -  The subject has history of consuming more than 14 units of alcoholic beverages per&#xD;
             week within 6 months prior to screening or has a history of alcoholism or&#xD;
             drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit =&#xD;
             12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor) or the subject&#xD;
             tests positive for alcohol or drugs of abuse (amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, and opiates)&#xD;
&#xD;
          -  The subject has taken part in strenuous exercise within 3 days before Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Early Phase Clinical Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 29, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Isavuconazole</keyword>
  <keyword>Repaglinide</keyword>
  <keyword>Caffeine</keyword>
  <keyword>BAL4815</keyword>
  <keyword>BAL8728</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Isavuconazole</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

